Tasfygo (tasurgratinib) / Eisai, SciClone - LARVOL DELTA

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Eisai Co., Ltd. | Trial completion date: Nov 2026 ➔ Aug 2027 | Trial primary completion date: Nov 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Hepatology

Exploratory circulating tumor (ct)DNA Analysis of Biomarkers Associated With Clinical Outcomes in Tasurgratinib‑treated, Fibroblast Growth Factor Receptor (FGFR)2 Fusion-Positive Cholangiocarcinoma (CCA) (ESMO 2026) - No abstract available

Biomarker • Circulating tumor DNA • Clinical • Clinical data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=51 | Completed | Sponsor: Eisai Co., Ltd. | Trial completion date: Mar 2027 ➔ Jun 2026 | Trial primary completion date: Mar 2027 ➔ Jun 2026 | Active, not recruiting ➔ Completed

Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • FGFR2 • HER-2

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion (clinicaltrials.gov) - P2 | N=63 | Completed | Sponsor: Eisai Co., Ltd. | Active, not recruiting ➔ Completed | Phase classification: PN/A ➔ P2

Phase classification • Trial completion • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2

FGFR2 Fusion Gene-Positive Solid Tumors (PubMed, Gan To Kagaku Ryoho) - "Pemigatinib (approved in 2021) demonstrated a response rate of 35.5%, futibatinib (approved in 2023) showed a response rate of 42%, and tasurgratinib (approved in 2024) achieved a response rate of 30.2%. Polyclonal on-target resistance to pan-FGFR inhibitors and increasing of FGFR2 kinase domain resistance mutations based on treatment history has been reported. Novel therapeutics, such as highly selective FGFR2 inhibitors and next-generation inhibitors, are developed and are expected to improve prognosis for patients with FGFR2 fusion-positive solid tumors."

Journal • Alopecia • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Immunology • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Retinal Disorders • Solid Tumor • FGFR2

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion (clinicaltrials.gov) - P2 | N=63 | Completed | Sponsor: Eisai Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Nov 2025 | Trial primary completion date: Mar 2026 ➔ Nov 2025

Trial completion • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Eisai Co., Ltd. | Trial completion date: Nov 2030 ➔ Nov 2032 | Trial primary completion date: Nov 2030 ➔ Nov 2032

Trial completion date • Trial primary completion date • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor • FGFR2

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=51 | Active, not recruiting | Sponsor: Eisai Co., Ltd. | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • FGFR2 • HER-2

SciClone Pharmaceuticals Announces NDA Acceptance of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in China (Sciclone Press Release) - "The application seeks approval for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy....Study 201 served as the key basis for the approval of tasurgratinib in Japan and is one of the primary foundations for its current NDA submission in China."

China filing • Biliary Tract Cancer

Results of a multicenter phase 2 basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration, including those with primary brain tumors: FORTUNE study. (SNO 2025) - "Primary endpoint was met in Group B. Tasurgratinib demonstrated clinical activity in pts with selected FGFR-mutated tumors. Additional recruitment of pts has been resumed (jRCT2031210043)."

Clinical • Metastases • P2 data • Pan tumor • Biliary Cancer • Biliary Tract Cancer • Brain Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR • FGFR1 • FGFR2

Results of a multicenter phase 2 basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration, including those with primary brain tumors: FORTUNE study. (WFNOS 2025) - "Primary endpoint was met in Group B. Tasurgratinib demonstrated clinical activity in pts with selected FGFR-mutated tumors. Additional recruitment of pts has been resumed (jRCT2031210043)."

Clinical • Metastases • P2 data • Pan tumor • Biliary Cancer • Biliary Tract Cancer • Brain Cancer • Cholangiocarcinoma • Solid Tumor • FGFR • FGFR1 • FGFR2

Sequential Fibroblast Growth Factor Receptor Inhibition in Intrahepatic Cholangiocarcinoma: Navigating an Evolving Landscape of Resistance and Opportunity-A Case Report and Current Opinion. (PubMed, Oncol Ther) - "Here, we report a case of FGFR2-rearranged iCCA where the patient achieved a radiographic partial response (PR) to tasurgratinib (a third-line FGFR inhibitor) following prior progression on pemigatinib and futibatinib. More broadly, this report serves as a basis for a current opinion on the evolving landscape of sequential FGFR inhibition in iCCA. We delve into the complexities of acquired resistance, dissect the arguments for and against prolonged FGFR pathway blockade, explore the impact of co-occurring genomic alterations, discuss the controversies, research priorities, and the urgent need for a balanced perspective to guide future clinical practice and trial design in this rapidly advancing but still uncertain field."

Journal • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR • FGFR2

Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study. (PubMed, Jpn J Clin Oncol) - P2 | "The primary endpoint (ORR) met the study's predefined success criteria. Tasurgratinib had a manageable safety profile consistent with previous reports and the known pharmacological profile of FGFR inhibitors."

Journal • P2 data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Eisai Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

NCCH2006/MK010 Trial (FORTUNE Trial) (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: National Cancer Center, Japan | Active, not recruiting ➔ Recruiting | N=46 ➔ 75 | Trial completion date: Dec 2024 ➔ Mar 2028 | Trial primary completion date: Dec 2024 ➔ Mar 2028

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Solid Tumor • ALK • BRAF • EGFR • FGFR2 • FGFR4 • KRAS • NRAS • NTRK • ROS1

First Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma with Tasurgratinib Following Regulatory Approval: A Case Report from Clinical Practice. (PubMed, Int J Mol Sci) - "We report the case of a 55-year-old female with advanced iCCA harboring an FGFR2-BICC1 fusion, who experienced a rapid clinical response to tasurgratinib following disease progression on gemcitabine, cisplatin, and durvalumab (GCD). This is the first report to describe the real-world clinical efficacy of tasurgratinib in an iCCA patient with FGFR2-BICC1 fusion. Our findings suggest that tasurgratinib can provide a rapid and durable response with manageable toxicity in molecularly selected patients who have progressed on standard therapies."

Journal • Anorexia • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Solid Tumor • BICC1 • FGFR2

A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study. (ASCO 2025) - P2 | "In Group B, the primary endpoint was met. Tasurgratinib demonstrated clinical activity in pts with selected FGFR-mutated tumors. Further study is needed to validate these findings."

Clinical • Metastases • P2 data • Pan tumor • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR • FGFR2

Effect of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2- Breast Cancer Preclinical Models. (PubMed, Cancers (Basel)) - "FGF signaling plays a role in resistance to CDK4/6 inhibitors and ET in ER+ BC. Tasurgratinib has the potential to exhibit significant antitumor activity in combination with ET against ER+ BC via FGF signaling inhibition. These findings indicate the therapeutic potential of tasurgratinib in treating ER+ BC."

Journal • Preclinical • Breast Cancer • Endocrine Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • FGF10 • FGF2 • FGFR1 • HER-2

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Eisai Co., Ltd. | Trial completion date: Nov 2033 ➔ Nov 2030 | Initiation date: Feb 2025 ➔ Aug 2025 | Trial primary completion date: Nov 2032 ➔ Nov 2030

Trial completion date • Trial initiation date • Trial primary completion date • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Tasurgratinib Succinate: First Approval. (PubMed, Drugs) - "The approval was based on the positive results of an open-label, single-arm, multicenter, phase II study conducted in Japan and China. This article summarizes the milestones in the development of tasurgratinib succinate leading to this first approval for biliary tract cancer."

Journal • Review • Biliary Cancer • Biliary Tract Cancer • Breast Cancer • Cholangiocarcinoma • Hepatology • Oncology • Solid Tumor • FGFR2

Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone (Eisai Press Release) - "Eisai...announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor tasurgratinib succinate...in the Greater China region (mainland China, Hong Kong, Macau, and Taiwan, 'licensed regions') to a subsidiary of SciClone Pharmaceuticals (Holdings) Limited (Headquarters: Shanghai, China, 'SciClone'). Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched. Under the terms of this agreement, Eisai will receive a contractual upfront payment. Additionally, Eisai will receive milestone payments based on the progress of development and regulatory approval, as well as sales milestone payments and certain royalties based on sales revenue after the product launch."

Licensing / partnership • Estrogen Receptor Positive Breast Cancer • HER2 Negative Breast Cancer

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Eisai Co., Ltd.

New trial • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of sacituzumab govitecan for breast cancer, fruquintinib for colorectal cancer, amivantamab for lung cancer, repotrectinib for lung cancer, tasurgratinib for biliary tract cancer, enfortumab vedotin plus pembrolizumab for urothelial cancer, and dabrafenib plus trametinib for glioma in Japan. (PubMed, Int J Clin Oncol) - No abstract available

Japanese regulatory • Journal • Biliary Cancer • Biliary Tract Cancer • Brain Cancer • Breast Cancer • CNS Tumor • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Glioma • Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer

Potential predictive biomarkers for a fibroblast growth factor receptor (FGFR) inhibitor: Phase 1b trial of tasurgratinib (E7090) with endocrine therapies (ET) for ER+, HER2+ recurrent/metastatic breast cancer (BC) resistant to CDK4/6 inhibitors (SABCS 2024) - P1 | "Part 1 included treatment with fulvestrant (FUL) 500 mg + E7090 (105 or 140 mg) or exemestane (EXE) 25 mg + E7090 (105 or 140 mg). These results emphasize that FGFR pathway activation evaluated with mRNA expression of selected genes at BL—rather than FGFR gene abnormalities—is a key molecular determinant for sensitivity to E7090, an FGFR inhibitor. Future validation of these biomarkers is necessary in a larger population of people with ER+/HER2− BC."

Biomarker • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CCND1 • ER • FGF19 • FGF3 • FGF4 • FGFR • FGFR1 • HER-2 • PIK3CA • TP53

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: Eisai Co., Ltd. | Trial completion date: Dec 2024 ➔ Mar 2026 | Trial primary completion date: Dec 2024 ➔ Mar 2026

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • FGFR • HER-2